| Lung Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.95 |
| Antineoplastic Drug |
0 |
0.74 |
| Small Cell Lung Cancer |
0 |
0.68 |
| Head and Neck Cancer |
0 |
0.61 |
| Tyrosine Kinase Inhibitor |
0 |
0.57 |
| Cancer |
0 |
0.56 |
| Colorectal Cancer |
0 |
0.54 |
| Lung |
0 |
0.52 |
| Genomic Medicine |
0 |
0.5 |
| Metastasis |
0 |
0.43 |
| Targeted Cancer Therapy |
0 |
0.4 |
| Toxicology |
0 |
0.39 |
| Biopsy |
0 |
0.99 |
| Receptors |
0 |
0.3 |
| EGFR Inhibitor |
0 |
0.27 |
| Chemotherapy |
0 |
0.26 |
| Epidermal Growth Factor Receptor |
0 |
0.26 |
| Tyrosine Kinase |
0 |
0.22 |
| Platinum |
0 |
0.15 |
| Glioblastoma |
0 |
0.12 |
| CT Scan |
0 |
0.09 |
| Colon Adenocarcinoma |
0 |
0.08 |
| Adenocarcinoma |
0 |
0.07 |
| Board Certification |
0 |
0.07 |
| Melanoma |
0 |
0.07 |
| Tumor |
0 |
0.07 |
| A-Scan Biometry |
0 |
0.04 |
| Adjuvant Therapy |
0 |
0.04 |
| BRAF |
0 |
0.04 |
| California |
0 |
0.04 |
| Care and Maintenance of Vision |
0 |
0.04 |
| Cataract |
0 |
0.04 |
| Central Nervous System |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Dyspnea |
0 |
0.04 |
| Glioblastoma Multiforme |
0 |
0.04 |
| Grant |
0 |
0.04 |
| Healthcare and Medical Technology |
0 |
0.04 |
| Humanized Monoclonal Antibody |
0 |
0.04 |
| Insurance |
0 |
0.04 |
| Meta-Analysis |
0 |
0.04 |
| Physiology |
0 |
0.04 |
| Quality of Life |
0 |
0.04 |
| Revenue and Practice Management |
0 |
0.04 |
| Scan |
0 |
0.04 |